OMER.O (OMER.O) News
Follow OMER.O (OMER.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
BRIEF — Omeros Corporation To Terminate Yartemlea Compassionate — Use Program In Europe Due To US Demand
Oct 16 (Reuters) — Omeros Corporation: Omeros Corporation Receives Chmp Negative Opinion Following Re-examination Of European Marketing Authorization Application For Narsoplimab In Ta-tma Omeros Corporation - To Terminat
NEWS | Oct 16, 2026, 10:37 AM UTC
L
EU Panel Upholds Negative Opinion on Omeros’ Narsoplimab Application
EMA's CHMP upheld its negative opinion on Omeros' narsoplimab marketing application following re-examination of its June 2026 decision. The application covers hematopoietic stem cell transplant-associated thrombotic micr
REGULATION | Oct 16, 2026, 10:22 AM UTC
H
Omeros Corporation Receives CHMP Negative Opinion Following Re — Examination of European Marketing Authorization Application for Narsoplimab in TA — TMA
For best results when printing this announcement, please click on link below: Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in
REGULATION | Oct 16, 2026, 10:22 AM UTC